Summary

North America liver fibrosis treatment market is expected to reach USD 16.87 billion by 2032 from USD 7.46 billion in 2024, growing at a substantial CAGR of 10.8% in the forecast period of 2025 to 2032.

Market Segmentation:
North America Liver Fibrosis Treatment Market, By Treatment Type (Medication and Surgery/Therapy), Stages ( F2, F1, F3, and F4), Indication (Non-Alcoholic Steatohepatitis (NASH), Hepatitis B & C-Induced Fibrosis, Alcoholic Liver Disease (ALD), Autoimmune Liver Diseases, Genetic Disorders, and Others), Gender(Male and Female), End User (Hospitals, Specialty Clinics, Clinics, Ambulatory and Research Centers, and Others), Distribution Channel (Direct Tender and Retail Sales), Country (U.S., Canada and Mexico) - Industry Trends & Forecast To 2032
Overview of North America Liver Fibrosis Treatment Market Dynamics:

Driver

• Increasing Prevalence of Liver Diseases
Restraint

• Limited Awareness of Liver Diseases
Opportunity

• Progress in Pipeline Products for Liver Fibrosis Treatment
Market Players:

The key market players operating in the North America liver fibrosis treatment market are listed below:

• Gilead Sciences, Inc.
• AbbVie Inc.
• Merck & Co., Inc.
• Novartis AG
• Intercept Pharmaceuticals, Inc.
• F. Hoffmann-La Roche Ltd
• Abbott
• La Renon Healthcare Pvt. Ltd.
• GENFIT SA
• Madrigal Pharmaceuticals
• Aligos Therapeutics
• Pfizer Inc.
• Enanta Pharmaceuticals, Inc.
• Bristol-Myers Squibb Company
• Vertex Pharmaceuticals Incorporated
• Takeda Pharmaceutical Company Limited
• Hepion Pharmaceuticals
• Echosens
• Galectin Therapeutics, Inc.
• Conatus Pharmaceuticals
• Tvardi Therapeutics
• Viking Therapeutics
• Calliditas Therapeutics AB
• Novomedix
• Galecto Biotech
• Pilant Therapeutics, Inc.
• Sagimet Biosciences
• Gyre Therapeutics, Inc.
• Akero Therapeutics, Inc.
• CureVac SE
• Novo Nordisk A/S
• Ipsen Pharma
• AdAlta Limited
• Alentis Therapeutics AG

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 INTRODUCTION 29
1.1 OBJECTIVES OF THE STUDY 29
1.2 MARKET DEFINITION 29
1.3 OVERVIEW OF THE NORTH AMERICA LIVER FIBROSIS TREATMENT MARKET 29
1.4 CURRENCY AND PRICING 31
1.5 LIMITATIONS 31
1.6 MARKETS COVERED 32
2 MARKET SEGMENTATION 36
2.1 MARKETS COVERED 36
2.2 GEOGRAPHICAL SCOPE 37
2.3 YEARS CONSIDERED FOR THE STUDY 38
2.4 DBMR TRIPOD DATA VALIDATION MODEL 39
2.5 MULTIVARIATE MODELLING 42
2.6 TREATMENT TYPE LIFELINE CURVE 43
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 44
2.8 DBMR MARKET POSITION GRID 45
2.9 MARKET END USER COVERAGE GRID 46
2.10 VENDOR SHARE ANALYSIS 47
2.11 SECONDARY SOURCES 48
2.12 ASSUMPTIONS 48
3 EXECUTIVE SUMMARY 49
4 PREMIUM INSIGHTS 52
4.1 PESTAL ANALYSIS 56
4.2 PORTERS FIVE FORCES ANALYSIS 57
4.2.1 LIVER TRANSPLANTATION VOLUME AND THEIR COST FOR LIVER FIBROSIS BY COUNTRY 58
4.2.2 ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES FOR LIVER FIBROSIS: VOLUME AND COST BY COUNTRY 59
4.2.3 PARTIAL HEPATECTOMY (LIVER RESECTION) COST BY COUNTRY 61
4.2.4 CELL-BASED THERAPY COST FOR LIVER FIBROSIS TREATMENT BY COUNTRY 62
4.3 EPIDEMIOLOGY 64
4.3.1 INCIDENCE OF ALL BY GENDER 64
4.3.2 TREATMENT RATE 64
4.3.3 TREATMENT RATE 65
4.3.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL 65
4.3.5 PATIENT TREATMENT SUCCESS RATES 66
4.4 MARKETED DRUG ANALYSIS 67
4.5 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES 72
4.5.1 PATIENT FLOW DIAGRAM 72
4.5.2 KEY PRICING STRATEGIES 73
4.5.3 KEY PATIENT ENROLLMENT STRATEGIES 75
5 NORTH AMERICA LIVER FIBROSIS TREATMENT MARKET: REGULATIONS 77
6 MARKET OVERVIEW 80
6.1 DRIVERS 82
6.1.1 INCREASING PREVALENCE OF LIVER DISEASES 82
6.1.2 RISING CONSUMPTION OF ALCOHOL 82
6.1.3 RISING LIVER TRANSPLANTATION RATES 83
6.1.4 GROWING INCIDENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) & NASH 84
6.2 RESTRAINTS 85
6.2.1 LIMITED AWARENESS OF LIVER DISEASES 85
6.2.2 REGULATORY CHALLENGES 85
6.3 OPPORTUNITIES 87
6.3.1 EMERGING TECHNOLOGIES AND ADVANCED TREATMENTS IN LIVER FIBROSIS MANAGEMENT 87
6.3.2 PROGRESS IN PIPELINE PRODUCTS FOR LIVER FIBROSIS TREATMENT 87
6.3.3 STRATEGIC MERGERS AND ACQUISITIONS AMONG THE KEY PLAYERS 88
6.4 CHALLENGES 90
6.4.1 LACK OF EFFECTIVE AND APPROVED ANTI-FIBROTIC DRUGS 90
6.4.2 HIGH COST OF TREATMENTS IN LIVER FIBROSIS CARE 90
7 NORTH AMERICA LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE 92
7.1 OVERVIEW 93
7.2 MEDICATION 96
7.2.1 ANTIVIRAL AGENTS 98
7.2.1.1 VELPATASVIR/SOFOSBUVIR 98
7.2.1.2 TENOFOVIR 98
7.2.1.3 LEDIPASVIR/SOFOSBUVIR 98
7.2.1.4 SOFOSBUVIR 98
7.2.1.5 ENTECAVIR 98
7.2.2 ANTIFIBROTIC AGENTS 100
7.2.2.1 OBETICHOLIC ACID 100
7.2.2.2 TGF-Β INHIBITORS 100
7.2.2.3 CONNECTIVE TISSUE GROWTH FACTOR (CTGF) INHIBITORS 100
7.2.2.4 LYSYL OXIDASE-LIKE 2 (LOXL2) INHIBITORS 100
7.2.2.5 OTHERS 100
7.2.3 ANTI-INFLAMMATORY DRUGS 102
7.2.3.1 CORTICOSTEROIDS 102
7.2.3.1.1 PREDNISONE 102
7.2.3.1.2 DEXAMETHASONE 102
7.2.3.2 TUMOR NECROSIS FACTOR (TNF) INHIBITORS 103
7.2.3.2.1 INFLIXIMAB 103
7.2.3.2.2 ETANERCEPT 103
7.2.3.3 INTERLEUKIN (IL) INHIBITORS 104
7.2.3.3.1 IL-6 INHIBITORS (TOCILIZUMAB) 104
7.2.3.3.2 IL-1 INHIBITORS (ANAKINRA) 104
7.2.4 IMMUNOSUPPRESSANTS 106
7.2.4.1 MYCOPHENOLATE MOFETIL 106
7.2.4.2 TACROLIMUS 106
7.2.4.3 CYCLOSPORINE 106
7.2.5 MARKETED DRUGS 107
7.2.5.1 VELPATASVIR/SOFOSBUVIR 107
7.2.5.2 TENOFOVIR 107
7.2.5.3 LEDIPASVIR/SOFOSBUVIR 107
7.2.5.4 OBETICHOLIC ACID (OCA) 108
7.2.5.5 SOFOSBUVIR 108
7.2.5.6 PIRFENIDONE 108
7.2.5.7 OTHERS 108
7.2.6 PIPELINE DRUGS 108
7.2.7 BRANDED DRUGS 109
7.2.7.1 EPCLUSA 109
7.2.7.2 VIREAD AND VEMLIDY 109
7.2.7.3 OCALIVA 109
7.2.7.4 HARVONI 110
7.2.7.5 SOVALDI 110
7.2.7.6 BARACLUDE 110
7.2.7.7 ACTOS 110
7.2.7.8 OTHERS 110
7.2.8 GENERIC DRUGS 110
7.2.9 ORAL 110
7.2.10 PARENTERAL 110
7.2.11 OTHERS 110
7.3 SURGERY/THERAPY 111
7.3.1 LIVER TRANSPLANTATION 112
7.3.2 ORTHOTOPIC LIVER TRANSPLANT (OLT) 112
7.3.3 LIVING DONOR LIVER TRANSPLANT (LDLT) 112
7.3.4 SPLIT LIVER TRANSPLANTATION 112
7.3.5 DOMINO LIVER TRANSPLANT 112
7.3.6 ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES 113
7.3.6.1 ENDOSCOPIC VARICEAL LIGATION (EVL) 113
7.3.6.2 TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) 113
7.3.6.3 LIVER ABLATION PROCEDURES 113
7.3.6.3.1 RADIOFREQUENCY ABLATION (RFA) 113
7.3.6.3.2 MICROWAVE ABLATION (MWA) 113
7.3.7 PARTIAL HEPATECTOMY (LIVER RESECTION) 114
7.3.7.1 SEGMENTAL RESECTION 114
7.3.7.2 LOBECTOMY 114
7.3.7.3 WEDGE RESECTION 114
7.3.8 CELL-BASED THERAPY 115
7.3.8.1 STEM CELL THERAPY 115
7.3.8.1.1 MESENCHYMAL STEM CELLS (MSCS) 115
7.3.8.1.2 HEMATOPOIETIC STEM CELLS (HSCS) 115
7.3.8.2 GENE THERAPY 116
7.3.8.2.1 CRISPR-BASED LIVER REGENERATION 116
7.3.8.2.2 HEPATIC STELLATE CELL (HSC) INHIBITORS 116
7.3.8.2.3 SIRNA-BASED THERAPIES 116
7.3.8.2.4 HEPATOCYTE APOPTOSIS INHIBITORS 116
7.3.8.2.4.1 OXIDATIVE STRESS INHIBITORS 117
7.3.8.2.4.2 EMRICASAN 117
7.3.8.2.4.3 PENTOXIFYLLINE 117
7.3.8.2.4.4 LOSARTAN 117
7.3.8.2.4.5 METHYL FERULIC ACID 117
7.3.8.2.4.6 OTHERS 117
7.4 OTHERS 117
8 NORTH AMERICA LIVER FIBROSIS TREATMENT MARKET, BY STAGES 118
8.1 OVERVIEW 119
8.2 F2 122
8.3 F1 123
8.4 F3 123
8.5 F4 124
9 NORTH AMERICA LIVER FIBROSIS TREATMENT MARKET, BY INDICATION 125
9.1 OVERVIEW 126
9.2 NON-ALCOHOLIC STEATOHEPATITIS (NASH) 129
9.3 HEPATITIS B & C-INDUCED FIBROSIS 130
9.3.1 CHRONIC HEPATITIS B VIRUS (HBV) FIBROSIS 130
9.3.2 CHRONIC HEPATITIS C VIRUS (HCV) FIBROSIS 130
9.4 ALCOHOLIC LIVER DISEASE (ALD) 131
9.5 AUTOIMMUNE LIVER DISEASES 132
9.5.1 AUTOIMMUNE HEPATITIS (AIH) 133
9.5.2 PRIMARY BILIARY CHOLANGITIS (PBC) 133
9.5.3 PRIMARY SCLEROSING CHOLANGITIS (PSC) 133
9.6 GENETIC DISORDERS 133
9.6.1 HEMOCHROMATOSIS 134
9.6.2 WILSON’S DISEASE 134
9.6.3 ALPHA-1 ANTITRYPSIN DEFICIENCY 134
9.7 OTHERS 134
10 NORTH AMERICA LIVER FIBROSIS TREATMENT MARKET, BY GENDER 135
10.1 OVERVIEW 136
10.2 MALE 139
10.2.1 40-55 YEARS 140
10.2.2 ABOVE 55 YEARS 140
10.2.3 BELOW 40 YEARS 140
10.3 FEMALE 141
10.3.1 ABOVE 55 YEARS 141
10.3.2 40-55 YEARS 141
10.3.3 BELOW 40 YEARS 141
11 NORTH AMERICA LIVER FIBROSIS TREATMENT MARKET, BY END USER 142
11.1 OVERVIEW 143
11.2 HOSPITALS 146
11.2.1 PUBLIC HOSPITALS 147
11.2.2 PRIVATE HOSPITALS 147
11.3 SPECIALTY CLINICS 147
11.3.1 HEPATOLOGY CLINICS 148
11.3.2 GASTROENTEROLOGY CLINICS 148
11.4 CLINICS 148
11.5 AMBULATORY AND RESEARCH CENTERS 149
11.6 OTHERS 150
12 NORTH AMERICA LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL 151
12.1 OVERVIEW 152
12.2 DIRECT TENDER 155
12.2.1 RETAIL SALES 156
12.2.1.1 HOSPITAL PHARMACY 156
12.2.1.2 RETAIL PHARMACY 156
12.2.1.3 ONLINE PHARMACY 156
13 NORTH AMERICA LIVER FIBROSIS TREATMENT MARKET, BY REGION 157
13.1 NORTH AMERICA 160
13.1.1 U.S. 180
13.1.2 CANADA 199
13.1.3 MEXICO 215
14 NORTH AMERICA LIVER FIBROSIS TREATMENT MARKET: COMPANY LANDSCAPE 231
14.1 COMPANY SHARE ANALYSIS: GLOBAL 231
15 SWOT ANALYSIS 232
16 COMPANY PROFILES 233
16.1 GILEAD SCIENCES, INC. 233
16.1.1 COMPANY SNAPSHOT 233
16.1.2 REVENUE ANALYSIS 234
16.1.3 COMPANY SHARE ANALYSIS 234
16.1.4 PRODUCT PORTFOLIO 235
16.1.5 RECENT DEVELOPMENT/NEWS 239
16.2 ABBVIE, INC. 241
16.2.1 COMPANY SNAPSHOT 241
16.2.2 REVENUE ANALYSIS 241
16.2.3 COMPANY SHARE ANALYSIS 242
16.2.4 PRODUCT PORTFOLIO 242
16.2.5 RECENT DEVELOPMENT 242
16.3 MERCK & CO, INC. 243
16.3.1 COMPANY SNAPSHOT 243
16.3.2 REVENUE ANALYSIS 244
16.3.3 COMPANY SHARE ANALYSIS 244
16.3.4 PRODUCT PORTFOLIO 244
16.3.5 RECENT DEVELOPMENT 244
16.4 NOVARTIS AG 245
16.4.1 COMPANY SNAPSHOTS 245
16.4.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS 246
16.4.3 COMPANY SHARE ANALYSIS 246
16.4.4 PRODUCT PORTFOLIO 246
16.4.5 PIPELINE PRODUCT PORTFOLIO 247
16.4.6 RECENT DEVELOPMENT 247
16.5 INTERCEPT PHARMACEUTICALS, INC. 248
16.5.1 COMPANY SNAPSHOTS 248
16.5.2 COMPANY SHARE ANALYSIS 248
16.5.3 REVENUE ANALYSIS AND SEGMENTED ANALYSIS 248
16.5.4 PRODUCT PORTFOLIO 249
16.5.5 PIPELINE PRODUCT PORTFOLIO 249
16.5.6 RECENT NEWS 250
16.6 ABBOTT 251
16.6.1 COMPANY SNAPSHOT 251
16.6.2 REVENUE ANALYSIS 251
16.6.3 PRODUCT PORTFOLIO 252
16.6.4 1.1.5 RECENT DEVELOPMENT 252
16.7 ALIGOS THERAPEUTICS 253
16.7.1 COMPANY SNAPSHOT 253
16.7.2 REVENUE ANALYSIS 253
16.7.3 PRODUCT PORTFOLIO 254
16.7.4 RECENT DEVELOPMENT 254
16.8 ALNICHE LIFE SCIENCES PVT. LTD. 256
16.8.1 COMPANY SNAPSHOT 256
16.8.2 PRODUCT PORTFOLIO 256
16.8.3 RECENT DEVELOPMENT 257
16.9 ALENTIS THERAPEUTICS AG 258
16.9.1 COMPANY SNAPSHOT 258
16.9.2 PIPELINE PRODUCT PORTFOLIO 258
16.9.3 RECENT DEVELOPMENT 258
16.10 ADALTA LIMITED 259
16.10.1 COMPANY SNAPSHOT 259
16.10.2 REVENUE ANALYSIS 259
16.10.3 PIPELINE PRODUCT PORTFOLIO 260
16.10.4 RECENT NEWS 260
16.11 AKERO THERAPEUTICS, INC. 261
16.11.1 COMPANY SNAPSHOT 261
16.11.2 REVENUE ANALYSIS 261
16.11.3 PIPELINE PRODUCT PORTFOLIO 261
16.11.4 RECENT DEVELOPMENT 262
16.12 BRISTOL-MYERS SQUIBB 263
16.12.1 COMPANY SNAPSHOT 263
16.12.2 REVENUE ANALYSIS 263
16.12.3 PRODUCT PORTFOLIO 264
16.12.4 RECENT DEVELOPMENT 264
16.13 CALLIDITAS THERAPEUTICS AB 265
16.13.1 COMPANY SNAPSHOT 265
16.13.2 PIPELINE PRODUCT PORTFOLIO 265
16.13.3 RECENT DEVELOPMENT 266
16.14 CUREVAC SE 267
16.14.1 COMPANY SNAPSHOT 267
16.14.2 REVENUE ANALYSIS 267
16.14.3 PRODUCT PORTFOLIO 268
16.14.4 RECENT DEVELOPMENT 268
16.15 CONATUSPHARMA 269
16.15.1 COMPANY SNAPSHOT 269
16.15.2 PRODUCT PORTFOLIO 269
16.15.3 RECENT DEVELOPMENT/NEWS 269
16.16 ENANTA PHARMACEUTICALS, INC. 270
16.16.1 COMPANY SNAPSHOT 270
16.16.2 REVENUE ANALYSIS 270
16.16.3 PRODUCT PORTFOLIO 271
16.16.4 RECENT DEVELOPMENT 271
16.17 ECHOSENS 272
16.17.1 COMPANY SNAPSHOT 272
16.17.2 PRODUCT PORTFOLIO 272
16.17.3 RECENT DEVELOPMENT/NEWS 273
16.18 F. HOFFMANN-LA ROCHE LTD 275
16.18.1 COMPANY SNAPSHOT 275
16.18.2 REVENUE ANALYSIS 275
16.18.3 COMPANY SHARE ANALYSIS 276
16.18.4 PRODUCT PORTFOLIO 276
16.18.5 RECENT DEVELOPMENT 276
16.19 GALECTO BIOTECH 277
16.19.1 COMPANY SNAPSHOT 277
16.19.2 REVENUE ANALYSIS 277
16.19.3 PIPELINE PRODUCT PORTFOLIO 277
16.19.4 RECENT DEVELOPMENT/NEWS 277
16.20 GALECTIN THERAPEUTICS, INC. 279
16.20.1 COMPANY SNAPSHOTS 279
16.20.2 REVENUE ANALYSIS AND SEGMENTAL ANALYSIS 279
16.20.3 PIPELINE PRODUCT PORTFOLIO 279
16.20.4 RECENT DEVELOPMENT 280
16.21 GYRE THERAPEUTICS, INC. 282
16.21.1 COMPANY SNAPSHOT 282
16.21.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS 283
16.21.3 PRODUCT PORTFOLIO 283
16.21.4 RECENT DEVELOPMENT/NEWS 284
16.22 GENFIT SA 285
16.22.1 COMPANY SNAPSHOTS 285
16.22.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS 285
16.22.3 PIPELINE PRODUCT PORTFOLIO 286
16.22.4 RECENT DEVELOPMENT 286
16.23 HEPION PHARMACEUTICALS 288
16.23.1 COMPANY SNAPSHOT 288
16.23.2 REVENUE ANALYSIS 288
16.23.3 PIPELINE PORTFOLIO 288
16.23.4 RECENT DEVELOPMENT 288
16.24 IPSEN PHARMA 290
16.24.1 COMPANY SNAPSHOT 290
16.24.2 REVENUE ANALYSIS 290
16.24.3 PIPELINE PRODUCT PORTFOLIO 291
16.24.4 RECENT NEWS/DEVELOPMENTS 291
16.25 LA RENON HEALTHCARE PVT. LTD. 293
16.25.1 COMPANY SNAPSHOT 293
16.25.2 PRODUCT PORTFOLIO 293
16.25.3 RECENT DEVELOPMENT 295
16.26 MADRIGAL PHARMACEUTICALS 296
16.26.1 COMPANY SNAPSHOTS 296
16.26.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS 296
16.26.3 PRODUCT PORTFOLIO 296
16.26.4 RECENT DEVELOPMENT 297
16.27 NOVO NORDISK A/S 298
16.27.1 COMPANY SNAPSHOT 298
16.27.2 REVENUE ANALYSIS 298
16.27.3 PIPELINE PRODUCT PORTFOLIO 299
16.27.4 RECENT DEVELOPMENT 299
16.28 NOVOMEDIX 300
16.28.1 COMPANY SNAPSHOT 300
16.28.2 PIPELINE PRODUCT PORTFOLIO 300
16.28.3 RECENT DEVELOPMENT 300
16.29 PILANT THERAPEUTICS, INC. 301
16.29.1 COMPANY SNAPSHOT 301
16.29.2 REVENUE ANALYSIS 301
16.29.3 PIPELINE PRODUCT PORTFOLIO 302
16.29.4 RECENT NEWS 302
16.30 PFIZER INC. 303
16.30.1 COMPANY SNAPSHOT 303
16.30.2 REVENUE ANALYSIS 303
16.30.3 PIPELINE PRODUCT PORTFOLIO 304
16.30.4 RECENT DEVELOPMENT/NEWS 304
16.31 SAGIMET BIOSCIENCES 305
16.31.1 COMPANY SNAPSHOTS 305
16.31.2 REVENUE ANALYSIS 305
16.31.3 1.1.4 PRODUCT PORTFOLIO 305
16.31.4 RECENT DEVELOPMENT/NEWS 306
16.32 TAKEDA PHARMACEUTICAL COMPANY LIMITED 307
16.32.1 COMPANY SNAPSHOT 307
16.32.2 REVENUE ANALYSIS 308
16.32.3 PIPELINE PRODUCT PORTFOLIO 308
16.32.4 PRODUCT PORTFOLIO 309
16.32.5 RECENT DEVELOPMENT 310
16.33 TVARDI THERAPEUTICS 311
16.33.1 COMPANY SNAPSHOT 311
16.33.2 PIPELINE PRODUCT PORTFOLIO 311
16.33.3 RECENT DEVELOPMENT/NEWS 312
16.34 VERTEX PHARMACEUTICALS INCORPORATED 313
16.34.1 COMPANY SNAPSHOT 313
16.34.2 REVENUE ANALYSIS 313
16.34.3 PRODUCT PORTFOLIO 314
16.34.4 RECENT DEVELOPMENT 315
16.35 VIKING THERAPEUTICS 317
16.35.1 COMPANY SNAPSHOT 317
16.35.2 REVENUE ANALYSIS 317
16.35.3 PIPELINE PRODUCT PORTFOLIO 317
16.35.4 RECENT DEVELOPMENT 318
17 QUESTIONNAIRE 319
18 RELATED REPORTS 323